{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:29:14Z","timestamp":1761629354316,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":1271,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1111\/ajt.15239","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T11:59:54Z","timestamp":1545911994000},"page":"1806-1819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optimal timing of hepatitis C treatment among HIV\/HCV coinfected ESRD patients: Pre- vs posttransplant"],"prefix":"10.1016","volume":"19","author":[{"given":"Brittany A.","family":"Shelton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Berdahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Sawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin P.","family":"Linas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux N.","family":"Mustian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhiannon D.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayme E.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.15239_bib1","unstructured":"Centers for Disease Control. Estimated HIV Incidence and Prevalence in the United States, 2010-2015. 2018. https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-supplemental-report-vol-23-1.pdf. Accessed November 21, 2018."},{"key":"10.1111\/ajt.15239_bib2","unstructured":"Centers for Disease Control. HIV\/AIDS and Viral Hepatitis. 2018. https:\/\/www.cdc.gov\/hepatitis\/populations\/hiv.htm. Accessed September 13, 2018."},{"issue":"suppl 1","key":"10.1111\/ajt.15239_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jis927","article-title":"An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection","volume":"207","author":"Kim","year":"2013","journal-title":"J Infect Dis."},{"issue":"6","key":"10.1111\/ajt.15239_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11904-016-0333-9","article-title":"Metabolic and cardiovascular complications in HIV\/HCV-co-infected patients","volume":"13","author":"Bedimo","year":"2016","journal-title":"Curr HIV\/AIDS Rep."},{"issue":"3","key":"10.1111\/ajt.15239_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/jmv.24353","article-title":"Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis","volume":"88","author":"Fabrizi","year":"2016","journal-title":"J Med Virol."},{"issue":"3","key":"10.1111\/ajt.15239_bib6","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.kint.2017.08.015","article-title":"Race but not hepatitis C co-infection affects survival of HIV(+) individuals on dialysis in contemporary practice","volume":"93","author":"Sawinski","year":"2018","journal-title":"Kidney Int."},{"issue":"3","key":"10.1111\/ajt.15239_bib7","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/SLA.0000000000001761","article-title":"Survival benefit of kidney transplantation in HIV-infected patients","volume":"265","author":"Locke","year":"2017","journal-title":"Ann Surg."},{"issue":"21","key":"10.1111\/ajt.15239_bib8","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1001\/jama.294.21.2726","article-title":"Deceased-donor characteristics and the survival benefit of kidney transplantation","volume":"294","author":"Merion","year":"2005","journal-title":"JAMA."},{"issue":"6","key":"10.1111\/ajt.15239_bib9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/TP.0000000000000479","article-title":"Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts","volume":"99","author":"Scalea","year":"2015","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.15239_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.7326\/M16-0560","article-title":"Realizing HOPE: the ethics of organ transplantation from HIV-positive donors","volume":"165","author":"Durand","year":"2016","journal-title":"Ann Intern Med."},{"issue":"10","key":"10.1111\/ajt.15239_bib11","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1111\/ajt.15040","article-title":"Population level outcomes and cost-effectiveness of Hepatitis C treatment pre versus post kidney transplant","volume":"18","author":"Shelton","year":"2018","journal-title":"Am J Transplant."},{"issue":"10","key":"10.1111\/ajt.15239_bib12","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1111\/ajt.14891","article-title":"Hepatitis C virus-infected kidney waitlist patients: treat now or treat later?","volume":"18","author":"Kiberd","year":"2018","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.15239_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modified the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol."},{"issue":"6","key":"10.1111\/ajt.15239_bib14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.7326\/M13-1829","article-title":"Hepatic decompensation in antiretroviral-treated HIV\/hepatitis C-coinfected compared to hepatitis C-monoinfected patients: a cohort study","volume":"160","author":"Re","year":"2014","journal-title":"Ann Intern Med."},{"issue":"3","key":"10.1111\/ajt.15239_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2215\/CJN.07460716","article-title":"Access to kidney transplantation among HIV-infected waitlist candidates","volume":"12","author":"Locke","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"9","key":"10.1111\/ajt.15239_bib16","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1681\/ASN.2014070726","article-title":"A national study of outcomes among HIV-infected kidney transplant recipients","volume":"26","author":"Locke","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"10.1111\/ajt.15239_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/ki.2015.74","article-title":"Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV\/HCV-coinfected recipients","volume":"88","author":"Sawinski","year":"2015","journal-title":"Kidney Int."},{"issue":"8","key":"10.1111\/ajt.15239_bib18","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1111\/ajt.13847","article-title":"Identification of optimal donor-recipient combinations among human immunodeficiency virus (HIV)-positive kidney transplant recipients","volume":"16","author":"Locke","year":"2016","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.15239_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jvh.12484","article-title":"Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver disease","volume":"23","author":"Padam","year":"2016","journal-title":"J Viral Hepatitis."},{"issue":"2","key":"10.1111\/ajt.15239_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.29071","article-title":"Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus\/hepatitis C virus coinfection","volume":"66","author":"Berenguer","year":"2017","journal-title":"Hepatology."},{"issue":"10","key":"10.1111\/ajt.15239_bib21","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ajt.14895","article-title":"The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes","volume":"18","author":"Axelrod","year":"2018","journal-title":"Am J Transplant."},{"issue":"1 Suppl 1","key":"10.1111\/ajt.15239_bib22","first-page":"S1-163","article-title":"The morbidity and mortality associated with kidney disease in an HIV-infected cohort in Puerto Rico","volume":"20","author":"Mayor","year":"2010","journal-title":"Ethn Dis. Winter."},{"issue":"8","key":"10.1111\/ajt.15239_bib23","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV."},{"key":"10.1111\/ajt.15239_bib24","first-page":"S102","article-title":"Efficacy and safety of glecaprevir\/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study","volume":"66","author":"Rockstroh","year":"2018","journal-title":"Clin Infect Dis."},{"issue":"9973","key":"10.1111\/ajt.15239_bib25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","volume":"385","author":"Sulkowski","year":"2015","journal-title":"Lancet."},{"issue":"5","key":"10.1111\/ajt.15239_bib26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"10","author":"Kucirka","year":"2010","journal-title":"Am J Transplant."},{"issue":"10","key":"10.1111\/ajt.15239_bib27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA."},{"issue":"4","key":"10.1111\/ajt.15239_bib28","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology."},{"issue":"1","key":"10.1111\/ajt.15239_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"Brau","year":"2006","journal-title":"J Hepatol."},{"issue":"2","key":"10.1111\/ajt.15239_bib30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology."},{"issue":"2","key":"10.1111\/ajt.15239_bib31","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1097\/MCG.0b013e3181e12c09","article-title":"Direct economic burden of chronic hepatitis C virus in a United States managed care population","volume":"45","author":"Davis","year":"2011","journal-title":"J Clin Gastroenterol."},{"issue":"3","key":"10.1111\/ajt.15239_bib32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"10.1111\/ajt.15239_bib33","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/gut.2005.064774","article-title":"Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C","volume":"55","author":"Grieve","year":"2006","journal-title":"Gut."},{"issue":"31","key":"10.1111\/ajt.15239_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6310","article-title":"Screening for hepatitis C among injecting drug users and in genitourinary medicine clinics: systematic reviews of effectiveness, modelling study and national survey of current practice","volume":"6","author":"Stein","year":"2002","journal-title":"Health Technol Assess."},{"issue":"5","key":"10.1111\/ajt.15239_bib35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2009.31","article-title":"Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study","volume":"104","author":"Bruno","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"21","key":"10.1111\/ajt.15239_bib36","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa1001197","article-title":"Outcomes of kidney transplantation in HIV-infected recipients","volume":"363","author":"Stock","year":"2010","journal-title":"N Engl J Med."},{"issue":"suppl 1","key":"10.1111\/ajt.15239_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 annual data report: kidney","volume":"18","author":"Hart","year":"2018","journal-title":"Am J Transplant."},{"issue":"7","key":"10.1111\/ajt.15239_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/cid\/cir076","article-title":"Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more","volume":"52","author":"Pearlman","year":"2011","journal-title":"Clin Infect Dis."},{"issue":"24","key":"10.1111\/ajt.15239_bib39","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA."},{"key":"10.1111\/ajt.15239_bib40","doi-asserted-by":"crossref","first-page":"e12829","DOI":"10.1111\/tid.12829","article-title":"Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney","volume":"20","author":"Shelton","year":"2018","journal-title":"Transpl Infect Dis."},{"year":"2017","series-title":"USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States 2017","key":"10.1111\/ajt.15239_bib41"},{"key":"10.1111\/ajt.15239_bib42","unstructured":"Scientific Registry of Transplant Recipients. Program-Specific Reports. 2018; https:\/\/www.srtr.org\/reports-tools\/program-specific-reports\/. Accessed May 10, 2018."},{"issue":"22","key":"10.1111\/ajt.15239_bib43","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N Engl J Med."},{"year":"2016","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","key":"10.1111\/ajt.15239_bib44"},{"issue":"4","key":"10.1111\/ajt.15239_bib45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50 000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med Care."},{"issue":"6","key":"10.1111\/ajt.15239_bib46","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/lt.23418","article-title":"Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: recognizing who can benefit","volume":"18","author":"Jay","year":"2012","journal-title":"Liver Transpl."},{"issue":"6","key":"10.1111\/ajt.15239_bib47","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1086\/597095","article-title":"HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness","volume":"48","author":"Paltiel","year":"2009","journal-title":"Clin Infect Dis."},{"issue":"6","key":"10.1111\/ajt.15239_bib48","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/TP.0000000000001310","article-title":"Cost-effectiveness of antibody-based induction therapy in deceased donor kidney transplantation in the United States","volume":"101","author":"Gharibi","year":"2017","journal-title":"Transplantation."},{"issue":"8","key":"10.1111\/ajt.15239_bib49","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med."},{"issue":"11","key":"10.1111\/ajt.15239_bib50","first-page":"1105","article-title":"Transplanting HCV-infected kidneys into uninfected recipients","volume":"377","author":"Goldberg","year":"2017","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1111\/ajt.15239_bib51","doi-asserted-by":"crossref","first-page":"e13365","DOI":"10.1111\/ctr.13365","article-title":"Knowledge, attitudes, and planned practice of HIV-positive to HIV-positive transplantation in US transplant centers","volume":"32","author":"Van Pilsum Rasmussen","year":"2018","journal-title":"Clin Transplant."},{"issue":"8","key":"10.1111\/ajt.15239_bib52","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/ajt.13308","article-title":"An assessment of HIV-infected patients dying in care for deceased organ donation in a United States urban center","volume":"15","author":"Richterman","year":"2015","journal-title":"Am J Transplant."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15239","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15239","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522091250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522091250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:25:16Z","timestamp":1761629116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522091250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S1600613522091250"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15239","relation":{},"ISSN":["1600-6135"],"issn-type":[{"type":"print","value":"1600-6135"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal timing of hepatitis C treatment among HIV\/HCV coinfected ESRD patients: Pre- vs posttransplant","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}